Medicare Pass-Through Payment System Needs Revision, MedPAC Says
This article was originally published in The Pink Sheet Daily
Anti-emetics illustrate the problem with the policy of providing separate payments for drugs over $50, MedPAC says. CMS is urged to use the pass-through process for all categories. MedPAC endorses CMS' proposed reimbursement change for Aranesp and Epogen in end-stage renal disease.
You may also be interested in...
Proposed revision would replace current policy of targeting physicians whose patients have average hematocrit levels over 37.5%. New policy would review erythropoietin claims with high hematocrit/hemoglobin levels and high doses.
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents
Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.